1.	Preliminary Efficacy and Safety of INNO-206 Compared to Doxorubicin in Advanced Soft Tissue Sarcoma Phase: Phase II Type: Treatment Status: Active Age: 15 to 80 Sponsor: Pharmaceutical / Industry Protocol IDs: INNO-206-P2-STS-01, NCT01514188
2.	Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 in Advanced Pancreatic Cancer Phase: Phase II Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: INNO-206-P2-PDA-01, NCT01580397
3.	Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors Phase: Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: ALDOXORUBICIN-P1-MTD-02, NCT01673438